Calcineurin Inhibitor–Free, mTOR‐Based Immunosuppression in Chimeric Antigen Receptor T‐Cell Therapy for Post‐Transplant Lymphoproliferative Disorder

ABSTRACT Introduction Relapsed/refractory post‐transplant lymphoproliferative disorder (PTLD) remains a challenging complication after solid organ transplantation (SOT), requiring complex balancing of immune‐suppressive therapy (IST) and lymphoma‐directed therapies. Methods We report the case of a 40‐year‐old female kidney‐pancreas transplant recipient with relapsing monomorphic PTLD treated with CD19‐chimeric antigen receptor (CAR) T cells therapy (axicabtagene ciloleucel). Results Tacrolimus discontinuation and immunosuppression with everolimus and corticosteroids permitted robust CAR T‐cell expansion, complete lymphoma remission, and preservation of graft function. In vitro studies showed that tacrolimus inhibited CAR T‐cell function, while everolimus preserved it, supporting the use of mTOR‐based, calcineurin‐inhibitor‐free IST during CAR T‐cell therapy in SOT recipients. Conclusion mTOR‐based, calcineurin inhibitor–free immunosuppression can preserve CAR T‐cell function and enable effective therapy in SOT recipients with PTLD.

Authors

Institutions

Publication Details

Journal
eJHaem
Published
2026-10-28
DOI
https://doi.org/10.1002/jha2.70437
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Calcineurin Inhibitor–Free, mTOR‐Based Immunosuppression in Chimeric Antigen Receptor T‐Cell Therapy for Post‐Transplant Lymphoproliferative Disorder

Sophie de Seigneux, Maria Mappoura, Kadiatou Baldet, Amandine Pradier et al.
eJHaem
CAR-T cell therapy research
article

Calcineurin Inhibitor–Free, mTOR‐Based Immunosuppression in Chimeric Antigen Receptor T‐Cell Therapy for Post‐Transplant Lymphoproliferative Disorder

Sophie de Seigneux, Maria Mappoura, Kadiatou Baldet, Amandine Pradier, Liza K.F. Ho, Sarah Morin, Federico Simonetta, Fadi Haidar, Astrid Melotti, Valérie Olivier, Kristof Levente Egervari, Chiara Bernardi, Francesco Bertoni, Thomas Longval, Yves Chalandon, Jean Villard, Julie Ducreux, Pragallabh Purwar, Sisi Wang, Yara Hajj Younes, Stavroula Marouridi‐Levrat, Carmen De Ramon Ortiz
article en

Abstract

ABSTRACT Introduction Relapsed/refractory post‐transplant lymphoproliferative disorder (PTLD) remains a challenging complication after solid organ transplantation (SOT), requiring complex balancing of immune‐suppressive therapy (IST) and lymphoma‐directed therapies. Methods We report the case of a 40‐year‐old female kidney‐pancreas transplant recipient with relapsing monomorphic PTLD treated with CD19‐chimeric antigen receptor (CAR) T cells therapy (axicabtagene ciloleucel). Results Tacrolimus discontinuation and immunosuppression with everolimus and corticosteroids permitted robust CAR T‐cell expansion, complete lymphoma remission, and preservation of graft function. In vitro studies showed that tacrolimus inhibited CAR T‐cell function, while everolimus preserved it, supporting the use of mTOR‐based, calcineurin‐inhibitor‐free IST during CAR T‐cell therapy in SOT recipients. Conclusion mTOR‐based, calcineurin inhibitor–free immunosuppression can preserve CAR T‐cell function and enable effective therapy in SOT recipients with PTLD.

eJHaemVol. 7(6)
University of Geneva (CH), Ente Ospedaliero Cantonale (CH), Institute of Oncology Research (CH), University Hospital of Geneva (CH), Istituto Oncologico della Svizzera Italiana (CH), Università della Svizzera italiana (CH)
Openalex Percentile: Top 16%
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon